Teradyne traded at $307.19, down 5.09%, in after-hours trading after its Q3 report. * The decline is primarily attributed to investors weighing the Q4 revenue guidance of $1.25 billion–$1.35 billion as a sequential step-down, despite beating Q3 estimates. * Q3 revenue was $1.306 billion and non-GAAP EPS was $2.29, both above analyst estimates. * The earnings-call discussion is scheduled for October 28, 2026.